Outset Medical, Inc.
|Company Name||Outset Medical, Inc.|
On June 13, 2022, after the market closed, Outset announced that it had implemented “a shipment hold on the distribution of its Tablo Hemodialysis System for home use pending” a review and clearance of a 510(k) application by the U.S. Food and Drug Administration (“FDA”). The Company withdrew its prior guidance and expected second quarter 2022 revenue of at least $25 million due to the shipment hold.
On this news, Outset’s stock fell as much as 33% during intraday trading on June 14, 2022, thereby injuring investors.
Submit Your Information
If you suffered a loss on your Outset Medical, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.